Don't change who we are but give us a chance: confronting the potential of community health worker certification for workforce recognition and exclusion.

Background: For community health workers (CHWs) and promotores de salud (CHWs who primarily serve Latinx communities and are grounded in a social, rather than a clinical model of care), the process of certification highlights the tension between developing a certified workforce with formal requirements (i.e., certified CHWs) and valuing CHWs, without formal requirements, based on their roles, knowledge, and being part of the communities where they live and work (i.

Spectral pulse shaping of a 5 Hz, multi-joule, broadband optical parametric chirped pulse amplification frontend for a 10 PW laser system.

We present a broadband optical parametric chirped pulse amplification (OPCPA) system delivering 4 J pulses at a repetition rate of 5 Hz. It will serve as a frontend for the 1.5 kJ, <150  fs, 10 PW laser beamline currently under development by a consortium of National Energetics and Ekspla.

Valve repair in aortic regurgitation without root dilatation--aortic valve repair.

Background: Aortic valve repair was established in the context of aortic root remodeling. Variable results have been reported for isolated valve repair. We analyzed our experience with isolated valve repair and compared the results with those of aortic root remodeling.

Valve-sparing aortic root replacement in bicuspid aortic valves: a reasonable option?

Objectives: Aortic dilatation occurs in many patients with bicuspid aortic valves. We have added root replacement using the remodeling technique originally designed for tricuspid aortic valves to bicuspid aortic valve repair for treatment of the dilated root. We compared the results of remodeling in bicuspid aortic valves with those in tricuspid aortic valves.

Aortic valve repair using a differentiated surgical strategy.

Background: Reconstruction of the aortic valve for aortic regurgitation (AR) remains challenging, in part because of not only cusp or root pathology but also a combination of both can be responsible for this valve dysfunction. We have systematically tailored the repair to the individual pathology of cusps and root.

Methods: Between October 1995 and August 2003, aortic valve repair was performed in 282 of 493 patients undergoing surgery for AR and concomitant disease.

Efficacy of three head-pointing devices for a mouse emulation task.

Today, there are three competing technologies (exemplified by five products) to provide head-pointing mouse emulation. Since the manufacturers of each of these devices claims to provide similar functionality, it can be difficult for the clinician to decide which is the appropriate device for a client. The current study compares the functional performance of the three input technologies using three commercially available devices, the HeadMaster Plus, Tracker 2000, and Tracer.

Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase.

A series of potent and highly selective time-dependent monocyclic beta-lactam inhibitors of human polymorphonuclear leukocyte elastase (PMNE, EC 3.4.21.

Orally active beta-lactam inhibitors of human leukocyte elastase. 2. Effect of C-4 substitution.

The effect of changing the C-4 substituent of 3,3-diethyl-1-[(benzylamino)carbonyl]-2-azetidinone on inhibition of HLE and in a model of HLE-induced lung damage in hamsters was explored. Substituents at this position do not appear to interact strongly with HLE with the most potent compounds having k(obs)/[I] = 6900 M-1 s-1. However, substituents at this position had a marked effect on in vivo activity.

Orally active beta-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones.

A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1- [[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model.